Skip to main content

Table 3 End organ abnormalities among patients with cytokine release syndrome

From: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

  Total patients with CRS (N = 51)
All grades Grades 1–2 Grades 3–4
Liver
 ALT high 25 (49) 24 (47) 1 (2)
 AST high 40 (78) 23 (45) 17 (33)
 Bilirubin high 22 (43) 22 (43) 0
Kidney
 Creatinine high 18 (35) 15 (29) 3 (6)
Pulmonary and vascular systems
 Hypotension 12 (24) 9 (18) 3 (6)
 Hypoxia 4 (8) 4 (8) 0
 Respiratory failure 1 (2) 0 1 (2)
Coagulopathya
 aPTT prolonged 31 (67) 28 (61) 3 (7)
 Fibrinogen decreased 17 (37) 0 17 (37)
  1. ALT alanine aminotransferase, aPTT activated partial thromboplastin time, AST aspartate aminotransferase, CRS cytokine release syndrome
  2. aOnly 46 patients had laboratory test results available (N = 46 was used as the denominator)